It is therefore reasonable to conclude that c-MET/EGFR are important biomarker signatures of tumorigenesis, tumor immune invasion, and poor prognoses, and thus can serve as attractive targets for the development of immune/chemotherapeutic strategies against CRC. The gene discussed is MET; the disease is neoplasm.